Related medicinesLutropin alfa

Where it comes from

Made in
Gonadotroph cells of the anterior pituitary, which make FSH too
Sent out by
Fast GnRH pulses favour it; a surge at mid-cycle when oestrogen flips from inhibiting to stimulating; steady pulses in men
Acts on
  • Ovarian theca cells and the dominant follicle
  • Corpus luteum
  • Testicular Leydig cells

What it does

  • Its mid-cycle surge ruptures the follicle and releases the egg, then turns the follicle into the corpus luteum
  • Drives testosterone from the Leydig cells
  • Rises after menopause and in testicular failure when the feedback is gone

In medicine

  • Home ovulation tests detect the urinary LH surge
  • Lutropin alfa, recombinant LH, is added to FSH in fertility treatment for women who lack it; hCG is usually used in its place to trigger ovulation 3
  • Measured with FSH to sort out amenorrhoea, delayed puberty and hypogonadism: high in gonadal failure, low in pituitary or hypothalamic causes

Beyond the body’s own use

  • Adding recombinant LH to FSH in IVF was reviewed across 14 trials and 2,612 women without a clear gain in pregnancy or live birth; the one group that may benefit is poor responders 1
  • Kisspeptin, which sits upstream of GnRH, has been tried as a gentler trigger than hCG: in 60 women at high risk of ovarian hyperstimulation, kisspeptin-54 matured eggs in 95 per cent and none developed moderate or worse hyperstimulation 2
  • Luteinizing hormone and chorionic gonadotropin are banned in sport in male athletes, because they raise testosterone from the testis; they are not prohibited for women 4
  • A urinary test shows the surge and not the egg: a follicle can luteinise without rupturing, so a positive strip is evidence that LH rose and not proof that ovulation followed

Sources

  1. Mochtar et al., Recombinant luteinizing hormone for controlled ovarian hyperstimulation, Cochrane Database of Systematic Reviews 2007
  2. Abbara et al., Kisspeptin-54 to trigger oocyte maturation in women at high risk of OHSS, Journal of Clinical Endocrinology and Metabolism 2015
  3. EMA assessment report, Luveris
  4. World Anti-Doping Agency, The Prohibited List, section S2

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.